Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Conditions:   HIV Infections;   Fatty Liver Disease Interventions:   Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day;   Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day;   Drug: Continue with their previous treatment. Any pre vious HAART that does not contain Rilpivirine. Sponsor:   Fundacion SEIMC-GESIDA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2023 Category: Research Source Type: clinical trials

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Conditions:   HIV Infections;   Fatty Liver Disease Interventions:   Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day;   Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day;   Drug: Continue with their previous treatment. Any pre vious HAART that does not contain Rilpivirine. Sponsor:   Fundacion SEIMC-GESIDA Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2023 Category: Research Source Type: clinical trials

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Conditions:   HIV Infections;   Fatty Liver Disease Interventions:   Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day;   Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day;   Drug: Continue with their previous treatment. Any pre vious HAART that does not contain Rilpivirine. Sponsor:   Fundacion SEIMC-GESIDA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2023 Category: Research Source Type: clinical trials

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Conditions:   HIV Infections;   Fatty Liver Disease Interventions:   Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day;   Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day;   Drug: Continue with their previous treatment. Any pre vious HAART that does not contain Rilpivirine. Sponsor:   Fundacion SEIMC-GESIDA Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2023 Category: Research Source Type: clinical trials

Nursing Counseling to the Change of Behavior of Alcohol Consumption in Patients in HAART
Conditions:   HIV;   Alcohol Drinking Interventions:   Behavioral: Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART;   Behavioral: Habitual Counseling Sponsors:   Universidad Peruana Cayetano Heredia;   John E. Fogarty International Center (FIC);   CARIBBEAN, CENTRAL AND SOUTH AMERICA NETWORK FOR HIV EPIDEMIOLOGY Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 13, 2019 Category: Research Source Type: clinical trials